文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

COAPT试验:继发性二尖瓣反流合并心衰患者TEER治疗后的住院与死亡率

Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

COAPT试验将614例心衰合并重度继发性二尖瓣反流患者随机分为TEER+GDMT组与单纯GDMT组。2年时TEER组任何心衰住院时间-首次事件率(34.8% vs 56.4%;HR: 0.51;95%CI: 0.39-0.66)和致死性心衰住院率(6.5% vs 12.6%;HR: 0.47;95%CI: 0.26-0.85)均低于单纯GDMT组。TEER组患者平均多存活且不住院约2个月(581±27天 vs 519±26天;P=0.002)。所有心衰住院均与2年死亡率独立相关,且不受治疗分组影响。

要点

  • TEER可降低心衰合并重度继发性二尖瓣反流患者的2年心衰住院和致死性心衰住院风险
  • TEER组患者2年内平均多存活且不住院约2个月
  • 心衰住院(无论致死与否)均独立关联2年死亡率升高,与治疗方式无关

核心结论

  • 在心衰合并重度继发性二尖瓣反流患者中,与单纯GDMT相比,TEER治疗降低了2年全因住院(致死性和非致死性)及心衰住院率,并增加了存活且不住院的时间。
  • 心衰住院与2年死亡率强烈相关,且这种关联在TEER和GDMT两组中一致。

研究设计与样本

  • COAPT试验为随机对照试验,纳入614例心衰合并重度继发性二尖瓣反流患者,随机分为TEER+GDMT组与单纯GDMT组。
  • 住院事件分为致死性(住院期间死亡)和非致死性(出院存活)。

主要发现

  • 2年时TEER组任何心衰住院的时间-首次事件率为34.8%,单纯GDMT组为56.4%(HR: 0.51;95%CI: 0.39-0.66)。
  • 2年时TEER组致死性心衰住院率为6.5%,单纯GDMT组为12.6%(HR: 0.47;95%CI: 0.26-0.85)。
  • TEER组全因非致死性和致死性住院率均低于单纯GDMT组。
  • 2年随访期间,TEER组患者平均存活且不住院天数为581±27天,单纯GDMT组为519±26天(P=0.002)。
  • 所有心衰住院(校正HR: 6.37;95%CI: 4.63-8.78)和非致死性心衰住院(校正HR: 1.78;95%CI: 1.27-2.49)均独立关联2年死亡率增加,两组间交互作用P值分别为0.34和0.39。

临床怎么用

  • 对于心衰合并重度继发性二尖瓣反流且符合COAPT入组标准的患者,TEER联合GDMT可减少心衰住院并增加存活且不住院时间。
  • 心衰住院事件应被视为死亡风险升高的重要标志,无论患者是否接受TEER治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of transcatheter edge-to-edge repair (TEER) on the rate and prognostic impact of hospitalizations in patients with heart failure (HF) and severe secondary mitral regurgitation is unknown. OBJECTIVES: This study sought to evaluate the effect of the MitraClip percutaneous edge-to edge repair system on fatal and nonfatal hospitalizations and their relationship with mortality in the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) trial. METHODS: Patients with HF (n = 614) with severe secondary mitral regurgitation were randomized to TEER plus guideline-directed medical therapy (GDMT) versus GDMT alone. Hospitalizations were classified as fatal if death occurred during that hospitalization or nonfatal if the patient was discharged alive. RESULTS: At 2 years, TEER treatment, compared with GDMT alone, resulted in lower time-to-first-event rates of any heart failure hospitalization (HFH) (34.8% vs 56.4%; HR: 0.51; 95% CI: 0.39-0.66) and fatal HFH (6.5% vs 12.6%; HR: 0.47; 95% CI: 0.26-0.85). TEER also resulted in lower rates of all-cause nonfatal and fatal hospitalizations. During the 2-year follow-up period, patients who underwent TEER spent an average of 2 more months alive and out of the hospital than did patients treated with GDMT alone (581 ± 27 days vs 519 ± 26 days; P = 0.002). All HFHs (adjusted HR: 6.37; 95% CI: 4.63-8.78) and nonfatal HFHs (adjusted HR: 1.78; 95% CI: 1.27-2.49) were consistently independently associated with increased 2-year mortality in both the TEER and GDMT groups (Pinteraction = 0.34 and 0.39, respectively). CONCLUSIONS: In the COAPT trial, compared with GDMT alone, patients with HF and severe secondary mitral regurgitation undergoing TEER with the percutaneous edge-to edge repair system had lower 2-year rates of fatal and nonfatal all-cause hospitalizations and HFH and spent more time alive and out of the hospital. HFHs were strongly associated with mortality, irrespective of treatment. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] and COAPT CAS [COAPT]; NCT01626079).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Giustino, Camaj, Kapadia, et al. Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial. J Am Coll Cardiol. 2022. PMID: 36357085. doi:10.1016/j.jacc.2022.08.803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。